Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-RT trial in locally advanced rectal cancer
ISRCTN18138369Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jan 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of durvalumab, oxaliplatin, fluorouracil, folinic acid and capecitabine in rectal adenocarcinoma (4 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Complete response rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
durvalumaboxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN18138369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18138369.